About UCSF Search UCSF UCSF Medical Center

UCSF Researchers Are Mapping DNA from 100,000 People for Unique Kaiser Database

By Jeffrey Norris, UCSF Science Cafe | January 13, 2010

Mother Nature's tightly held secrets to healthy aging are in danger of being wrested away. The genes we inherit, the lives we lead and the places we live all affect our chances to evade major diseases and to maintain health as we grow older.

To help sort out how variations in these contributing factors influence health risks, Kaiser Permanente's Division of Research is creating one of the world's largest genetic and environmental information resources for health research, called the Research Program on Genes, Environment, and Health (RPGEH).

"This is going to be the largest and most comprehensive database for doing genetic epidemiology research," says Neil Risch, PhD, head of the Institute for Human Genetics at UCSF and co-chair of the Department of Epidemiology. Risch is an adjunct investigator at the Kaiser Permanente Division of Research and co-director of the RPGEH.

In September 2009, the RPGEH and UCSF received $25 million in federal stimulus funds. The source was a new, two-year grant from the National Institutes of Health. The funds will enable Risch and colleagues to genotype DNA from 100,000 RPGEH participants. The genotyping project is a collaboration between the UCSF Institute for Human Genetics and the RPGEH.

As a result of this funding, in just a few years, scientists around the world will be able to tap into a new data resource, which will be the biggest of its kind to focus on genetic variation and environmental exposures in an older population. The average age of individuals whose genetic information will be genotyped for the project is 65.

More than 125,000 Kaiser members already have contributed saliva samples to the RPGEH for DNA genotyping.


Read more at Jeffrey Norris, UCSF Science Cafe

UCSF Scientist Wins $89M Grant to Study Anal Cancer In HIV-Infected People

By Elizabeth Fernandez    |   UCSF.edu | November 22, 2013

UCSF Scientist Wins $89M Grant to Study Anal Cancer In HIV-Infected People

Joel Palefsky, MD

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

The total amount of the award over the life of the grant is projected to be approximately $89 million.

Anal cancer disproportionately affects HIV-infected men and women, but the rate of infection is rising among people who do not have HIV and without active intervention, and the number of cases is expected to continue to grow in the general population.

Like cervical cancer and some oral cancers, most cases of anal cancer are associated with human papillomavirus (HPV). Vaccination has been shown to reduce the risk, but the majority of HIV-infected individuals currently at risk for anal cancer are older than age 26, do not qualify for vaccination, and may already have been exposed to the form of HPV known to cause anal cancer.

“Given these strong biological similarities, it is very possible that biomarkers and treatments identified in the study will be applicable to cervical and HPV-associated oral cancer as well,” said Joel Palefsky, MD, a UCSF professor of medicine and principal investigator of the anal cancer project.

The study will focus on determining the effectiveness of treating anal high-grade squamous intraepithelial lesions (HSIL), which are caused by chronic HPV infection, in reducing the incidence of anal cancer in HIV-infected men and women.

Combined with the possibility that anal cancer is preventable, the incidence of anal cancer is unacceptably high and calls for urgent intervention, Palefsky said.

“Compared with the general population, the incidence of anal cancer is increased more than 100-fold among some risk groups of HIV-infected persons, including many who are successfully treated with combination antiretroviral therapy,” Palefsky said. “There is evidence that anal HSIL is the precursor to invasive anal cancer, which makes it a great target for prevention.”

Read more at UCSF.edu